Cite
A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.
MLA
Novella-Navarro, Marta, et al. “A Treat-to-Target Approach for Gout Confers Renoprotective Effect in Patients with Chronic Kidney Disease Stage 3.” Rheumatology International, vol. 40, no. 7, July 2020, pp. 1081–87. EBSCOhost, https://doi.org/10.1007/s00296-020-04517-4.
APA
Novella-Navarro, M., Cabrera-Alarcon, J. L., Diaz-Torne, C., Aramburu-Muñoz, F., Janta, I., Ortega de la O, M. C., Prada-Ojeda, A., Sala-Icardo, L., Urruticoechea-Arana, A., García de la Peña Lefebvre, P., & Calvo-Aranda, E. (2020). A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3. Rheumatology International, 40(7), 1081–1087. https://doi.org/10.1007/s00296-020-04517-4
Chicago
Novella-Navarro, Marta, Jose Luis Cabrera-Alarcon, Cesar Diaz-Torne, Francisco Aramburu-Muñoz, Iustina Janta, Maria Carmen Ortega de la O, Alejandro Prada-Ojeda, et al. 2020. “A Treat-to-Target Approach for Gout Confers Renoprotective Effect in Patients with Chronic Kidney Disease Stage 3.” Rheumatology International 40 (7): 1081–87. doi:10.1007/s00296-020-04517-4.